RetatrutideResearch, Evidence & Safety Profile

Retatrutide is an investigational peptide drug developed by Eli Lilly and Company (Indianapolis, Indiana). It is a single synthetic peptide that acts as a triple hormone receptor agonist, activating three distinct targets simultaneously: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor. This triple-agonist mechanism distinguishes it from currently approved obesity medications, which target one (semaglutide: GLP-1 only) or two (tirzepatide: GLP-1 and GIP) receptors — see the retatrutide vs tirzepatide comparison for the side-by-side breakdown.

Retatrutide is designed for once-weekly subcutaneous injection. Its Phase 2 trial, published in the New England Journal of Medicine in 2023, reported mean body weight reductions of up to 24.2% at the highest dose (12 mg) over 48 weeks — a result that at the time represented the highest weight loss ever reported for an investigational drug in a published clinical trial. Phase 2 data also showed significant improvements in waist circumference, blood pressure, lipids, and glycemic markers.

As of May 2026, retatrutide is not approved by the U.S. Food and Drug Administration or any other regulatory agency for any indication. It is in Phase 3 clinical development under the TRIUMPH (TRIple agonist for Underlying Metabolic Problems with High weight) program, which includes trials for obesity, obstructive sleep apnea, and knee osteoarthritis. On May 21 2026, Lilly announced that the pivotal TRIUMPH-1 obesity trial met its primary endpoint, with 28.3% mean weight loss at 12 mg over 80 weeks and 30.3% at 104 weeks in the BMI ≥35 subgroup. A previously untested 4 mg low-dose arm produced approximately 19% weight loss. Full TRIUMPH-1 results are expected at the American Diabetes Association 2026 Scientific Sessions in June. Regulatory submission to the FDA is expected following the full Phase 3 readout. Other next-generation incretin candidates include the GLP-1 + amylin combination CagriSema, the recently announced amylin analog petrelintide, the GLP-1/glucagon dual agonist survodutide, the oral GLP-1/amylin amycretin, and the first oral non-peptide GLP-1 receptor agonist Foundayo (orforglipron).

Regulatory caution: Retatrutide is an investigational compound. It has not been reviewed for safety and efficacy at any dose for any indication outside of clinical trial protocols. Any use outside of a properly conducted clinical trial is unsanctioned and carries unknown risks.

Retatrutide's effects arise from simultaneous activation of three incretin and metabolic hormone receptor pathways:

• GLP-1 receptor agonism: GLP-1 (glucagon-like peptide-1) is an incretin hormone produced by intestinal L-cells. GLP-1 receptor activation stimulates glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon release, slows gastric emptying, and activates hypothalamic satiety centers — reducing appetite and food intake. This is the primary mechanism shared by semaglutide.
• GIP receptor agonism: GIP (glucose-dependent insulinotropic polypeptide) is produced by intestinal K-cells. GIP receptor activation amplifies glucose-stimulated insulin secretion and promotes favorable effects on adipose tissue metabolism. The synergistic combination of GLP-1 and GIP agonism — as seen with tirzepatide — produces greater weight loss than GLP-1 agonism alone. This additive effect is preserved in retatrutide.
• Glucagon receptor agonism: Glucagon is traditionally associated with raising blood glucose by stimulating hepatic glucose output. However, glucagon receptor activation also strongly stimulates hepatic fat oxidation (fat burning in the liver), increases energy expenditure, and promotes thermogenesis. When combined with GLP-1 agonism — which counteracts the hyperglycemic effect of glucagon — the metabolic benefits of glucagon receptor activation (increased energy expenditure and fat oxidation) can be captured without the glycemic downside. This third agonist component is what makes retatrutide mechanistically distinct from tirzepatide and is the proposed reason for its superior weight loss magnitude.

The net result of triple receptor activation is synergistic appetite suppression, enhanced insulin secretion, increased hepatic fat oxidation, and elevated energy expenditure — a combination that produces substantially greater caloric deficit and weight loss than dual or single receptor approaches.

The following potential benefits are based on Phase 2 human clinical trial data (NEJM 2023) and early Phase 3 data reported by Eli Lilly. All findings are from controlled clinical trials and may not be representative of uncontrolled use.

• Substantial body weight reduction: Phase 2 results showed mean weight loss of 17.5% (4 mg), 19.5% (8 mg), and 24.2% (12 mg) over 48 weeks versus −2.1% placebo. The pivotal Phase 3 TRIUMPH-1 obesity trial (reported by Lilly on May 21 2026) hit its primary endpoint with 28.3% mean weight loss at 12 mg over 80 weeks (≈70.3 lbs absolute mean loss). In the BMI ≥35 subgroup extended to 104 weeks, mean weight loss reached 30.3%. A previously untested 4 mg low-dose arm produced approximately 19% mean weight loss (≈47.2 lbs) — a result that may matter clinically because the lower dose is expected to have a more favorable gastrointestinal tolerability profile than the 12 mg dose used in earlier trials. Full TRIUMPH-1 data, including subgroup analyses, are expected at the ADA 2026 Scientific Sessions in June.
• Waist circumference reduction: Phase 2 participants showed clinically meaningful reductions in waist circumference — a proxy for visceral adiposity and cardiometabolic risk.
• Cardiometabolic improvements: Phase 2 demonstrated improvements in blood pressure, lipid profiles (LDL, triglycerides, HDL), and glycemic markers — effects expected given the mechanism and consistent with the GLP-1 drug class.
• Obstructive sleep apnea: TRIUMPH-OSA is a dedicated trial exploring retatrutide for obstructive sleep apnea — a condition strongly associated with obesity and for which weight loss produces meaningful symptom reduction.
• Knee osteoarthritis (TRIUMPH-4): Phase 3 TRIUMPH-4 enrolled 445 adults with obesity or overweight and knee osteoarthritis (without diabetes) and randomized them 1:1:1 to retatrutide 9 mg, 12 mg, or placebo over 68 weeks. Topline results reported mean body weight reductions of 26.4% (9 mg) and 28.7% (12 mg) versus 2.1% placebo, alongside WOMAC pain subscale reductions of up to 4.5 points (≈75.8%). In a post hoc analysis, 14.1% of the 9 mg arm and 12% of the 12 mg arm were free of knee pain at 68 weeks compared with 4.2% on placebo. The OA findings are encouraging and consistent with the magnitude of weight loss, but they are secondary to the primary weight-loss endpoint and have not yet appeared in a peer-reviewed publication as of May 2026.
• Potentially greater weight loss plateau resistance: The glucagon receptor component may increase resting energy expenditure, which could partially counteract the metabolic adaptation (slowed metabolism) that limits long-term weight loss with GLP-1 agonists alone. This hypothesis is being evaluated in ongoing trials.

Retatrutide's safety profile in Phase 2 is broadly consistent with the GLP-1 drug class, with some important considerations related to its additional glucagon receptor activity.

• Gastrointestinal effects (most common): Nausea, vomiting, diarrhea, and constipation were the most frequently reported adverse effects in Phase 2, particularly during dose escalation. These are consistent with GLP-1 agonism and are typically transient. The highest-dose groups (8 mg, 12 mg) had higher rates of GI events than lower doses.
• Discontinuation rate: Phase 2 had a dose-dependent discontinuation rate due to adverse events: 3.9% (4 mg), 6.3% (8 mg), 16.2% (12 mg). The 12 mg group's higher discontinuation rate reflects the tolerability tradeoffs at maximum efficacy dosing.
• Heart rate increase: A modest dose-dependent increase in resting heart rate has been observed, consistent with glucagon receptor agonism. Mean increases of approximately 5–10 bpm were reported in Phase 2. This warrants monitoring in individuals with pre-existing cardiovascular conditions.
• Lipase and amylase elevations: Modest elevations in pancreatic enzymes were observed, as with other GLP-1 class drugs. No cases of pancreatitis were reported in Phase 2, but this remains a class-level concern to monitor.
• Muscle mass considerations: Rapid, large-magnitude weight loss with GLP-1 class drugs is associated with loss of lean mass alongside fat mass. Whether retatrutide's glucagon component affects lean mass differently than dual agonists is not yet established. High protein intake and resistance training are typically recommended to mitigate this risk.
• Unknown long-term safety: As an investigational compound, retatrutide's long-term safety profile — beyond Phase 2 follow-up — is not fully characterized. Phase 3 data and post-market surveillance (if approved) will establish the long-term risk picture.

The GLP-1 drug class carries a class-wide warning for thyroid C-cell tumors observed in rodents. Whether this translates to human risk is uncertain and under ongoing evaluation. Individuals with a personal or family history of medullary thyroid carcinoma or MEN-2 syndrome should not use GLP-1 agonist drugs.

Disclaimer: Retatrutide is investigational and not approved for any indication. The following doses are from published clinical trial protocols for educational purposes only. These are not recommendations for self-administration.

Phase 2 trial dose escalation protocol (subcutaneous injection, once weekly):

• 1 mg: Starting dose for all participants; 4 weeks at this dose
• 2 mg: Week 4–8 escalation
• 4 mg: Maintenance dose for the lowest experimental group
• 8 mg: Intermediate maintenance dose
• 12 mg: Maximum maintenance dose — highest efficacy, highest adverse event rate

Dose escalation in the trial was conducted gradually over several months to improve tolerability. The Phase 3 TRIUMPH program includes maintenance dosing at 4 mg and 9 mg in addition to 12 mg to characterize the dose-response relationship more fully.

Retatrutide has the most promising efficacy signal of any investigational obesity drug in clinical development as of 2026, though Phase 3 primary endpoint data has not yet been fully peer-reviewed and published.

• Phase 2 (NEJM 2023): The pivotal Phase 2 trial enrolled 338 adults with obesity (BMI ≥ 30) or overweight with comorbidities. Over 48 weeks, mean weight loss was dose-dependent: 17.5% (4 mg), 19.5% (8 mg), 24.2% (12 mg) versus −2.1% placebo. These results were published in the New England Journal of Medicine in 2023 and garnered significant attention for exceeding all prior published obesity drug results at that time.
• Phase 3 TRIUMPH program: Lilly launched the TRIUMPH clinical program in 2023–2024, comprising multiple trials including TRIUMPH-1 (obesity/overweight) and TRIUMPH-4 (formerly TRIUMPH-OA, in adults with obesity and knee osteoarthritis). The program evaluates 4 mg, 9 mg, and 12 mg maintenance doses.
• TRIUMPH-1 (pivotal obesity trial) — May 21 2026 topline: Lilly reported that TRIUMPH-1 met its primary endpoint. Reported topline numbers include 28.3% mean body weight loss at 12 mg over 80 weeks (≈70.3 lbs), 30.3% at 104 weeks in the BMI ≥35 subgroup, and approximately 19% (≈47.2 lbs) at the previously untested 4 mg dose. The 4 mg arm is potentially relevant because it suggests a tolerability-friendly dose tier may still produce clinically meaningful weight loss. These data are from a company press release; full results are expected at the ADA 2026 Scientific Sessions in June, with peer-reviewed publication anticipated thereafter. As of the press release, no fatal or unexpected serious safety signals had been disclosed.
• TRIUMPH-4 (knee osteoarthritis): Reported topline results indicate up to 28.7% mean body weight loss at 68 weeks alongside a 75.8% reduction in WOMAC knee pain — but these data are from an investor press release and have not yet appeared in a peer-reviewed publication as of May 2026.
• Regulatory timeline: With the TRIUMPH-1 primary endpoint hit and the full readout expected at ADA 2026 (June), Lilly is expected to file a New Drug Application (NDA) with the FDA following the complete Phase 3 readout. FDA review timelines are typically 6–12 months for priority review designations, which retatrutide would likely qualify for. Regulatory approval, if granted, is not anticipated before 2027.
• Comparative context: In published Phase 3 data, tirzepatide (Mounjaro/Zepbound) achieved up to 22.5% mean weight loss over 72 weeks in SURMOUNT-1 (Jastreboff et al., NEJM 2022). Semaglutide (Wegovy) achieved approximately 14.9% over 68 weeks in STEP 1 (Wilding et al., NEJM 2021). Retatrutide's 28.3% TRIUMPH-1 topline suggests a meaningfully larger mean effect size, but the comparison is indirect — no head-to-head trial data between retatrutide and either tirzepatide or semaglutide currently exists.

As of April 2026, retatrutide is an investigational new drug (IND) in active Phase 3 clinical development. It has not received FDA approval, EMA approval, or approval from any other regulatory agency for any indication.

• United States: Investigational. Available only within approved clinical trial protocols. Not compoundable — it is a large-molecule biologic manufactured under proprietary processes, not a simple compound that pharmacy compounders can legally replicate.
• European Union: No regulatory status established. Phase 3 trials are ongoing.
• Off-label or grey market access: Unlike some peptides that have been available through compounding pharmacies, retatrutide's status as a proprietary large-molecule drug makes unauthorized access extremely limited. Any source claiming to supply retatrutide outside of a clinical trial should be regarded with serious skepticism — identity, purity, and safety of such products cannot be verified.
• Expected timeline: NDA filing expected 2026. If approved on standard priority review, market availability could come in late 2027 at the earliest. This is speculative and depends on the outcome of regulatory review.